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CD133 in the Selection of Epidermal
Stem Cells in Mice: Steps in the Right
Direction
Anna S. Nordvig1, David M. Owens1,2 and Rebecca J. Morris3
Charruyer and colleagues (this issue) report two significant advances to the field
of cutaneous keratinocyte stem cells: a pair of new selectable markers that
recognize a subset of a6þCD34þ label-retaining cells, and an in vivo limiting
dilution assay for keratinocyte stem cells with long-term repopulating ability.
This work has important implications for keratinocyte stem cell identification
and assay, as well as for the identification of target cells in non-melanoma
skin cancer.
Journal of Investigative Dermatology (2012) 132, 2492–2494; doi:10.1038/jid.2012.322
The cutaneous epithelium, including
the pilosebaceous unit, is a continually
renewing tissue that normally balances
cellular proliferation in the basal layer
with loss from the suprabasal layers
through terminal differentiation. Cellular
proliferation is governed by a relatively
larger population of transit-amplifying
cells and a smaller population of stem
cells that are ultimately responsible
for epithelial maintenance and repair.
Over the past decade, measurable pro-
gress has been made in identifying and
characterizing stem cell subsets in hair
follicles (for review please see Arwert
et al., 2012). Several of these markers
are illustrated in Figure 1. During this
time, we have learned that one of the
merits of understanding hair follicle
stem cell biology is the high therapeutic
potential for use in treating skin disease.
Along these lines, the identification of
additional selectable markers that fur-
ther enrich for high-capacity hair follicle
stem cells is likely to bolster their poten-
tial regenerative therapeutic application.
Stem cells from the cutaneous epi-
thelium are recognized not only by their
cell surface markers (both positive and
negative) but also by their functional
activities, typically by in vitro colony
formation and by their ability to recon-
stitute grafts with the epidermis, hair,
and sebaceous glands. As is the case
with the selectable determinants, the
various in vitro and in vivo functional
assays have both proponents and critics.
Charruyer and colleagues (2012, this
issue) address all of the aforementioned
stem cell characteristics and present
advances on two fronts. First, this group
identified a pair of new selectable mar-
kers for hair follicle stem cells; second,
they developed a new quantitative
in vivo assay for long-term keratinocyte
repopulating units in the follicular epi-
thelium. Although the former might fur-
ther confound the relationships among
the plethora of existing markers for hair
follicle bulge cells, the new subpopu-
lation represents a subset of the a6
integrinþCD34þ cells (Trempus et al.,
2003). The latter may resolve a pro-
blem that has dogged the most common
existing graft assay. With regard to
clonogenic capacity, the investigators
developed a functional in vitro assay
for clonogenic keratinocytes that does
not select for long-term repopulating
keratinocytes; however, these findings
are a little difficult to interpret, as the
harvesting methods and culture media
differ from those published previously,
and comparative studies were not
conducted.
CD133 was investigated as a select-
able epidermal stem cell marker
because it has been widely associated
with progenitor status in many organs.
Therefore, it is not surprising that anti-
bodies to CD133 recognized a subset of
progenitors from the hair follicle bulge.
TMRM, a fluorescent derivative of
rhodamine 123, was chosen because
murine embryonic stem cells with
high mitochondrial membrane potential
(DCm) exhibited decreased differentia-
tion and increased teratoma formation.
Those of us who in the 1990s attempted
to emulate Spangrude and Johnson
(1990) and struggled longingly with
Rh123 as a means for enriching for
quiescent and actively cycling keratino-
cyte stem cells greet the present success
with TMRM with considerable excite-
ment.
Charruyer and colleagues (2012)
approached the standard skin graft
model somewhat differently from that
of other investigators, performing a limi-
ting dilution of enriched keratinocyte
subpopulations by subcutaneous injec-
tion, resulting in the formation of epi-
thelial cysts, similar to the method used
by Schober and Fuchs (2011). Conse-
quently, the Ghadially group (Charruyer
et al., 2012) achieved a 5.2-fold
enrichment with CD133þDCmhi kerati-
nocytes over the a6þCD34þ controls.
Moreover, this enriched subpopulation
displayed superior long-term repopulat-
ing and self-renewal abilities; it was
composed of label-retaining cells, but
retained the ability to reconstitute an epi-
thelium with the epidermis, hair follicles,
and sebaceous glands. Moreover, the
long-term grafts were reconstituted by
single cells. This method is an informa-
tive departure from the existing method
of grafting with a cell slurry. Although the
slurry method produces epidermal and
hair follicles, apparently even differen-
tiated keratinocytes can reconstitute
such grafts (Mannik et al., 2010), leaving
one to wonder whether keratinocytes of
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various degrees of maturity can reorga-
nize hair follicles when grafted in high
cell numbers.
In contrast, the advancement made by
the in vitro clonogenic assay is some-
what more difficult to interpret, because
it departs from most of the current
methods using murine-adapted varia-
tions on Rheinwald and Green (1975).
On one hand, Morris and Potten (1994)
have demonstrated that [3H]thymidine
label-retaining cells in vivo are clono-
genic in vitro (using a custom medium
and irradiated 3T3); however, selectable
markers to determine their phenotype
were not available when these studies
were conducted. Moreover, it is not
clear how the lack of in vitro colony
formation by long-term repopulating
cells reported by the Ghadially labo-
ratory relates to the report by Blanpain
et al. (2004) in the Fuchs laboratory,
where individual colonies from selected
a6highCD34þ and a6lowCD34þ kerati-
nocytes were cultured for a number of
weeks from single cells and then grafted
together with hair inductive mesenchy-
mal cells to produce epithelium with
hair and sebaceous glands.
Furthermore, keratinocyte stem cells
have long been implicated as target cells
for non-melanoma skin cancer (Owens
and Watt, 2003), and the identification
of CD133 in a subset of normal hair
follicle bulge stem cells, as shown by
Ghadially and co-workers (Charruyer
et al., 2012), may have important impli-
cations for skin tumorigenesis. Although
CD133 is a transmembrane protein of
unknown function, as neither ligands
nor signaling pathways have been
found to associate with it, multiple lines
of evidence indicate that the presence of
CD133 on the cell surface may serve as a
functionally relevant biomarker for carci-
nogenesis. For example, in a variety of
tumor types including colon, pancreatic,
gallbladder, ovarian, lung, glioblastoma,
and melanoma, CD133 is a marker of
tumor-initiating cells (TICs) that show
high capacity for self-renewal, asym-
metric division to propagate differen-
tiated tumor bulk, the ability to switch
between quiescent and proliferative states,
and the ability for multiple rounds of
tumor propagation from a single or few
cells (Pardal et al., 2003; Gires, 2011).
In addition, CD133 expression does
appear to serve as an important pro-
gnostic factor for some cancer types
(Gires, 2011). However, genetic disru-
ption of CD133 does not perturb the
tumor-initiating capacity of neoplastic
cells, suggesting that CD133 may not
have a direct functional role in tumori-
genesis (Gires, 2011).
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Figure 1. Schematic of hair follicle progenitors illustrating the distinct structural components of the pilosebaceous unit, including the sebaceous gland,
isthmus, bulge, secondary hair germ, and dermal papilla. Boxes outline the cellular markers that are associated with keratinocyte progenitor or stem cell pools
in each hair follicle compartment. The two new markers identified by Charruyer and colleagues (2012) are highlighted in darker blue.
Clinical Implications
 CD133þDCmhigh keratinocytes are a subset of a6-integrinþCD34þ bulge
stem cells that is enriched for long-term repopulating stem cells.
 Enrichment for high-capacity keratinocyte stem cells may find application
in construction of skin equivalents for grafting in patients with burns and
poorly healing wounds.
 CD133þDCmhigh keratinocytes may represent a subset of initiating cells in
non-melanoma skin cancer.
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Recently, CD133 was detected in
subsets of neoplastic cells in human
primary cutaneous squamous cell carci-
nomas (SCCs) with TIC characteristics
(Patel et al., 2012), which raises two
important questions regarding the signi-
ficance of CD133 in non-melanoma
skin cancer. First, do CD133þ SCC-
initiating cells descend from trans-
formed CD133þ keratinocyte hair
follicle stem cells? Second, are there
common regulatory mechanisms that
underlie the regenerative and self-
renewal capacities of normal and neo-
plastic CD133þ keratinocytes? Recent
studies using genetic pulse–chase label-
ing approaches to genetically tag epider-
mal stem cells have helped to address the
first question by demonstrating that bulge
stem cells are susceptible to oncogenic
Ras and serve as a cell of origin for SCCs,
whereas transit cell populations are
unable to initiate SCCs under the same
conditions (reviewed in Thieu et al.,
2012). As for the latter question, the
further characterization of the CD133þ
bulge stem cell subset may be critical to
our understanding of the cellular basis for
SCC initiation and progression.
In summary, Charruyer and collea-
gues (2012) have presented significant
advances to the field of cutaneous kera-
tinocyte stem cells, including a pair of
new selectable markers that represent a
subset of a6þCD34þ label-retaining
cells and a new in vivo limiting dilu-
tion assay for keratinocyte stem cells
with long-term repopulating ability. This
work has important implications for
keratinocyte stem cell identification,
culture, and assay, as well as for identi-
fying the target cells in the pathogenesis
of non-melanoma skin cancer.
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Out of the Skin of Babes: Measuring
the Full Impact of Atopic Dermatitis
in Infants and Young Children
Amy S. Paller1 and Mary-Margaret Chren2
Valid psychometric instruments should be culturally adapted and refined with use.
Neri et al. present an excellent example of this process for the Childhood Atopic
Dermatitis Impact Scale. The work emphasizes that psychometric measurement
continues to develop and reminds us that optimal care of children with atopic
dermatitis requires considering its multidimensional effects on both the children
and their families.
Journal of Investigative Dermatology (2012) 132, 2494–2496; doi:10.1038/jid.2012.354
Atopic dermatitis (AD) manifests initially
during the preschool years in B90% of
affected individuals and has been shown
to have a significant impact on the
quality of life (QOL) of patients and their
families (Chamlin and Chren, 2010).
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